Prostate Cancer
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
October 13, 2023
Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients.
October 12, 2023
MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.
October 12, 2023
Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
October 11, 2023
A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer.
October 11, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
October 11, 2023
Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer.
October 11, 2023
Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study
October 10, 2023